Keyphrases
Patient-derived Xenograft
100%
Glioblastoma
100%
Combination Treatment
100%
9-ING-41
100%
Chemoresistant
100%
Nitrosourea
100%
Glycogen Synthase kinase-3 Inhibitors
100%
Cyclohexyl
100%
Human Glioblastoma
66%
Chemotherapy
33%
Glycogen Synthase Kinase 3 (GSK3)
33%
Bioluminescence Imaging
16%
Tumor Growth
16%
Patient Demographics
16%
Antitumor Activity
16%
Treatment Effect
16%
Clinical Evaluation
16%
Tumor
16%
Tumor Progression
16%
Overall Survival
16%
Glioblastoma multiforme
16%
Putative Drug Targets
16%
Cancer Cells
16%
Chemoresistance
16%
Immunohistochemical Staining
16%
Tumor Survival
16%
Immunoblotting
16%
Mouse Brain
16%
Resistance to Chemotherapy
16%
Antitumor Effect
16%
Investigational New Drug
16%
Positive Regulator
16%
Partial Response
16%
Reporter Construct
16%
Bioluminescence
16%
No Response
16%
Apoptosis Assay
16%
Difficult-to-treat Patients
16%
Pharmacology, Toxicology and Pharmaceutical Science
Lomustine
100%
Glycogen Synthase Kinase 3 Inhibitor
100%
Glioblastoma
100%
Chemotherapy
42%
Tumor Growth
28%
Glycogen Synthase Kinase 3
28%
Antitumor Activity
14%
Western Blot
14%
Clinical Trial
14%
Apoptosis Assay
14%
Malignant Neoplasm
14%
Overall Survival
14%
Neoplasm
14%
Drug Resistance
14%
Neuroscience
Glycogen Synthase Kinase 3 Inhibitor
100%
Nitrosourea
100%
Glycogen Synthase Kinase 3
33%
Bioluminescence
33%
Staining Technique
16%
Apoptosis Assay
16%
Drug Resistance
16%
Immunoblotting
16%
Mouse Brain
16%